Jane Street Group LLC Sells 17,450 Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS)

Jane Street Group LLC lessened its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 55.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 14,270 shares of the company’s stock after selling 17,450 shares during the period. Jane Street Group LLC owned 0.09% of Sensus Healthcare worth $83,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Truvestments Capital LLC purchased a new position in shares of Sensus Healthcare in the third quarter valued at about $32,000. Cubist Systematic Strategies LLC bought a new position in Sensus Healthcare in the 2nd quarter worth approximately $156,000. Marshall Wace LLP grew its holdings in Sensus Healthcare by 152.4% during the 2nd quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after buying an additional 46,732 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the second quarter valued at approximately $95,000. Finally, Renaissance Technologies LLC raised its position in shares of Sensus Healthcare by 34.4% during the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after buying an additional 100,294 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Performance

SRTS stock opened at $6.77 on Thursday. The firm has a market cap of $110.95 million, a PE ratio of 11.88 and a beta of 1.21. The firm has a fifty day moving average price of $7.69 and a 200 day moving average price of $6.71. Sensus Healthcare, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $9.33.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright raised their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th. Maxim Group lifted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.